A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state

Abstract

Emicizumab, a factor (F)VIIIa-function mimetic therapeutic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment for people with hemophilia A (PwHA). However, non-clinical studies suggest that the maximum cofactor activity of emicizumab is lower than international standard activity (100 IU/dL of FVIII), leaving room for further improvement. Since not all PwHA experienced zero treated bleeds, increased cofactor activity would be beneficial for such patients. Here, we report NXT007, a BsAb against FIXa and FX developed through further engineering of emicizumab. While emicizumab has a common light chain, advances in antibody engineering enabled us to identify a more potent BsAb with two distinct new light chains, and following extensive mutational optimization of the two emicizumab-derived heavy chains and two light chains, the resulting NXT007 exerted in vitro thrombin generation (TG) activity in hemophilia A plasma corresponding to that at 100 IU/dL of FVIII when coagulation is triggered by tissue factor. NXT007 demonstrated potent hemostatic activity in an acquired hemophilia A model in non-human primates at much lower dosage than emicizumab, consistent with an around 30-fold dose shift in the in vitro TG activity between NXT007 and emicizumab. Moreover, together with Fc engineering that enhanced FcRn binding and reduced in vivo clearance, we demonstrate that NXT007 could be effective at much lower dosage with a longer dosing interval compared to emicizumab. These non-clinical results suggest that NXT007 is expected to maintain a non-hemophilic range of coagulation potential in PwHA and provides a rationale for its clinical testing.

Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A

“…In addition, we describe how this technology was applied to NXT007, an anti-FIXa/FX bispecific humanized IgG 4 antibody with kappa and lambda LCs that has better coagulation activity than emicizumab. 38 We thoroughly assessed the optimal FAST-Ig design for NXT007, not only for preferential cognate HC/LC and HC/HC pairing, but also for pharmacological activity, physicochemical properties, immunogenicity, pharmacokinetics, and structure. Its applicability in a stable line of Chinese hamster ovary (CHO) cells, as well as its transient expression in Expi293F cells, were examined.…”